Oragenics, Inc. (OGEN) Updates on its potential COVID-19 Vaccine, expects to file an IND in 2021
The biotechnology firm is developing its vaccine candidate against SARS-CoV-2. Oragenics anticipate the Phase 1 trial of TerraCoV2 beginning in mid-2021 following the approval in 2023. Shares of Oragenics, Inc. (OGEN) made a strong movement on Wednesday following the Zacks Small-Cap Research that revealed OGEN’s plans and development of its novel COVID-19 vaccine candidate, TerraCoV2. […]
These 4 Companies Are Ending the Week Strong
The NASDAQ’s 1.0% gain led the market yesterday, and the S&P 500 and DJIA posted fractional gains. After passing its previous all-time high earlier in the week, markets aren’t sure where to go from here. Stocks are still performing strongly in spite of the inherent risks, but that could change on the drop of a […]
